FDA to End Emergency Use Authorization for Invivyd's Covid-19 Prevention Shot

Dow Jones07-06

Invivyd said regulators are ending emergency use authorization for its Covid-19 prevention medication, Pemgarda.

The Food and Drug Administration sent Invivyd a notice of termination, with the designation set to end June 29 of next year.

The Department of Health and Human Services is winding down emergency authorizations related to Covid-19 for drugs and biological products, as well as medical devices, after concluding that the circumstances for those authorizations had abated.

Pemgarda is an investigational antibody authorized in March 2024 for prevention of Covid-19 in adults and adolescents with moderate-to-severe immune compromise due to certain medical conditions or their use of immunosuppressive medications.

Marc Elia, Invivyd's board chairman, said the end of the formal emergency for Covid-19 products was "in many ways overdue," as the designation isn't the same as a product approval.

"We feel as though a full approval of Pemgarda is well-warranted at this time by the totality of demonstrated safety and efficacy data," he said.

Invivyd is in active dialogue with FDA on next steps.

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

July 06, 2026 11:58 ET (15:58 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2649678176?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-06 23:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2649678176","market":"sg","top_or_hot":-1,"title":"FDA to End Emergency Use Authorization for Invivyd's Covid-19 Prevention Shot","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Invivyd said regulators are ending emergency use authorization for its Covid-19 prevention medication, Pemgarda. \n</p>\n<p>\n  The Food and Drug Administration sent Invivyd a notice of termination, with the designation set to end June 29 of next year. \n</p>\n<p>\n  The Department of Health and Human Services is winding down emergency authorizations related to Covid-19 for drugs and biological products, as well as medical devices, after concluding that the circumstances for those authorizations had abated. \n</p>\n<p>\n  Pemgarda is an investigational antibody authorized in March 2024 for prevention of Covid-19 in adults and adolescents with moderate-to-severe immune compromise due to certain medical conditions or their use of immunosuppressive medications. \n</p>\n<p>\n  Marc Elia, Invivyd's board chairman, said the end of the formal emergency for Covid-19 products was \"in many ways overdue,\" as the designation isn't the same as a product approval. \n</p>\n<p>\n  \"We feel as though a full approval of Pemgarda is well-warranted at this time by the totality of demonstrated safety and efficacy data,\" he said. \n</p>\n<p>\n  Invivyd is in active dialogue with FDA on next steps. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 06, 2026 11:58 ET (15:58 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA to End Emergency Use Authorization for Invivyd's Covid-19 Prevention Shot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA to End Emergency Use Authorization for Invivyd's Covid-19 Prevention Shot\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-06 23:58</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Invivyd said regulators are ending emergency use authorization for its Covid-19 prevention medication, Pemgarda. \n</p>\n<p>\n  The Food and Drug Administration sent Invivyd a notice of termination, with the designation set to end June 29 of next year. \n</p>\n<p>\n  The Department of Health and Human Services is winding down emergency authorizations related to Covid-19 for drugs and biological products, as well as medical devices, after concluding that the circumstances for those authorizations had abated. \n</p>\n<p>\n  Pemgarda is an investigational antibody authorized in March 2024 for prevention of Covid-19 in adults and adolescents with moderate-to-severe immune compromise due to certain medical conditions or their use of immunosuppressive medications. \n</p>\n<p>\n  Marc Elia, Invivyd's board chairman, said the end of the formal emergency for Covid-19 products was \"in many ways overdue,\" as the designation isn't the same as a product approval. \n</p>\n<p>\n  \"We feel as though a full approval of Pemgarda is well-warranted at this time by the totality of demonstrated safety and efficacy data,\" he said. \n</p>\n<p>\n  Invivyd is in active dialogue with FDA on next steps. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 06, 2026 11:58 ET (15:58 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IVVD","symbol_name":"Invivyd, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2649678176","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2649678176","pubTimestamp":1783353480,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Invivyd said regulators are ending emergency use authorization for its Covid-19 prevention medication, Pemgarda.The Food and Drug Administration sent Invivyd a notice of termination, with the designation set to end June 29 of next year.The Department of Health and Human Services is winding down emergency authorizations related to Covid-19 for drugs and biological products, as well as medical devices, after concluding that the circumstances for those authorizations had abated.Pemgarda is an investigational antibody authorized in March 2024 for prevention of Covid-19 in adults and adolescents with moderate-to-severe immune compromise due to certain medical conditions or their use of immunosuppressive medications.Marc Elia, Invivyd's board chairman, said the end of the formal emergency for Covid-19 products was \"in many ways overdue,\" as the designation isn't the same as a product approval.\"We feel as though a full approval of Pemgarda is well-warranted at this time by the totality of dem","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IVVD":"Invivyd, Inc.","BK4139":"生物科技","BK4585":"ETF&股票定投概念","BK4539":"次新股","BK4588":"碎股","LABU":"三倍做多标普生物-Direxion"},"translate_title":"FDA将终止Invivyd COVID-19预防疫苗的紧急使用授权","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LABU":1.5,"IVVD":0.9},"content_text":"Invivyd said regulators are ending emergency use authorization for its Covid-19 prevention medication, Pemgarda. \n\n\n  The Food and Drug Administration sent Invivyd a notice of termination, with the designation set to end June 29 of next year. \n\n\n  The Department of Health and Human Services is winding down emergency authorizations related to Covid-19 for drugs and biological products, as well as medical devices, after concluding that the circumstances for those authorizations had abated. \n\n\n  Pemgarda is an investigational antibody authorized in March 2024 for prevention of Covid-19 in adults and adolescents with moderate-to-severe immune compromise due to certain medical conditions or their use of immunosuppressive medications. \n\n\n  Marc Elia, Invivyd's board chairman, said the end of the formal emergency for Covid-19 products was \"in many ways overdue,\" as the designation isn't the same as a product approval. \n\n\n  \"We feel as though a full approval of Pemgarda is well-warranted at this time by the totality of demonstrated safety and efficacy data,\" he said. \n\n\n  Invivyd is in active dialogue with FDA on next steps. \n\n\n \n\n\n  Write to Dean Seal at dean.seal@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 06, 2026 11:58 ET (15:58 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory,merge","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2649678176","isCrawlerRequest":true}